Leading ADC candidate HDP-101 continues to demonstrate favorable safety and tolerability profile; clinical trial progresses into ninth cohort with increased dose of 175 µg/kg Delay in significant milestone payment leads to extensive cost-saving measures, including a 75% reduction in workforce and focus on leading ADC project HDP-101 Presentation of new clinical data of HDP-101 at the […]
Dundee, UK, 09 October 2025 – Glen Clova Scientific (GCS), a biotechnology company developing breakthrough therapeutics for treatment of immuno-dermatological conditions, is pleased to announce the establishment of its Clinical Advisory Board (CAB). Read more…
– Dr Paul Brennan to present on the association of early biomarker modulation with long term clinical outcomes from the MATCH Ph II study of non-engineered macrophages in cirrhosis – Dr Lara Campana to present on anti-inflammatory and anti-fibrotic effects of regenerative macrophage therapy in models of liver fibrosis Edinburgh and London, UK, 9 October […]
Hansa Biopharma on 2nd October announced the raise of approximately USD 71 million through directed share issue, with strong support from new shareholders such as Polar Capital LLP, as well as existing shareholders.
How can companies with promising science secure the capital they need to develop drugs What does pharma need to fill their pipelines as they look to negotiate looming patent cliffs London, UK, 7 October 2025: Optimum Strategic Communications (Optimum), the specialist life sciences communications consultancy, will be hosting its 17th Annual Healthcare Investor Conference on Thursday 9 October […]
